GEN Exclusives

More »

GEN News Highlights

More »
Nov 16, 2006

MethylGene and Envivo Receive $1.5M to Advance Huntington’s Disease Research

  • MethylGene and EnVivo Pharmaceuticals entered into a collaborative agreement with CHDI, a nonprofit organization that is pursuing biotechnology approaches to rapidly discover and develop treatments for Huntington’s disease (HD). MethylGene and EnVivo formed a collaboration in February, 2005 focused on MethylGene’s HDAC technology for use in neurodegenerative diseases.

    In this collaboration, CHDI will provide financial and preclinical research support to MethylGene to enhance its collaboration with EnVivo Pharmaceuticals to progress histone deacetylase (HDAC) inhibitors for the treatment of HD. MethylGene will receive up to $1.5 million in initial funding for the identification, design, and synthesis of new isotype-selective HDAC inhibitors for potential use in treating Huntington’s disease as well as support for other preclinical pharmacology testing. MethylGene and EnVivo retain the exclusive right to develop and commercialize any clinical candidates that arise from the collaboration.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »